The company said it will seek an expanded indication for the left atrial appendage closure device after it met all safety and ...

Physicians wrestled with endpoint composition, low event rates, a possible difference in ischemic strokes, and more.

CHAMPION-AF shows Boston Scientific's Watchman FLX as a safe, effective first-line option for stroke risk reduction in ...

Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrilla ...

For patients with nonvalvular atrial fibrillation (AFib) who had no contraindications to taking oral anticoagulants, the use ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...

In one of the largest studies of its kind, a trial of Boston Scientific’s small, permanent cardiac implant showed that it could potentially serve as an alternative to long-term blood thin | Boston ...

The biggest names in cardiology tech gathered in New Orleans for the American College of Cardiology (ACC) Scientific Sessions ...

Study suggests a path forward for device therapy, though caveats are plenty ...

A new Watchman device at McLaren Port Huron offers eligible AFib patients an alternative to long‑term blood thinners to help ...

SAN FRANCISCO — Thirteen months after percutaneous left atrial appendage closure (LAAC), outcomes did not differ whether closure was performed using the Amulet (Abbott Cardiovascular) or the Watchman ...